Cloprostenol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cloprostenol
Accession Number
DB11507
Type
Small Molecule
Groups
Vet approved
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Cloprostenol sodium81129I41BJ55028-72-3IFEJLMHZNQJGQU-KXXGZHCCSA-M
Categories
UNII
52EJR3Y9IN
CAS number
54276-21-0
Weight
Average: 424.92
Monoisotopic: 424.1652664
Chemical Formula
C22H29ClO6
InChI Key
VJGGHXVGBSZVMZ-QIZQQNKQSA-N
InChI
InChI=1S/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1
IUPAC Name
(5Z)-7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid
SMILES
[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\[H])=C(/[H])[C@@]([H])(O)COC1=CC=CC(Cl)=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Cloprostenol.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Cloprostenol.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Cloprostenol.
7-NitroindazoleThe metabolism of Cloprostenol can be increased when combined with 7-Nitroindazole.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cloprostenol.
AceclofenacThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Acemetacin.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Cloprostenol.
AcetaminophenThe metabolism of Cloprostenol can be increased when combined with Acetaminophen.
AcetazolamideThe metabolism of Cloprostenol can be increased when combined with Acetazolamide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Dodwell SC: Cloprostenol and pregnancy termination. Vet Rec. 1979 Jan 27;104(4):83-4. [PubMed:433123]
  2. Boyd PA: Cloprostenol and pregnancy termination. Vet Rec. 1979 Jan 27;104(4):84. [PubMed:433124]
  3. Drummond JN: Cloprostenol and pregnancy termination. Vet Rec. 1979 Jan 6;104(1):21. [PubMed:433103]
  4. Johnson CT: Cloprostenol and pregnancy termination. Vet Rec. 1979 Feb 17;104(7):151. [PubMed:452355]
  5. Bowler J, Brown ED, Crossley NS, Heaton DW, Lilley TJ, Rose N: Double bond isomers of cloprostenol. Prostaglandins. 1979 Jun;17(6):789-800. [PubMed:504688]
  6. Harker DB: Letter: Cloprostenol in controlled bleeding. Vet Rec. 1975 Nov 29;97(22):437-8. [PubMed:1216432]
  7. Perera BM, Bongso TA, Abeynaike P: Oestrus synchronisation in goats using cloprostenol. Vet Rec. 1978 Apr 8;102(14):314. [PubMed:565969]
  8. Day AM, Southwell SR: Termination of pregnancy in goats using cloprostenol. N Z Vet J. 1979 Oct;27(10):207-8. [PubMed:295100]
  9. Rao AR, Rao SV: Treatment of suboestrus in buffaloes with cloprostenol. Vet Rec. 1979 Aug 25;105(8):168-9. [PubMed:574679]
  10. Barr DA: Cloprostenol for treatment of silent heat. N Z Vet J. 1977 Dec;25(12):402. [PubMed:276752]
External Links
ChemSpider
4470590
BindingDB
50085910
RxNav
2606
ChEMBL
CHEMBL37853
ZINC
ZINC000004536236
Wikipedia
Cloprostenol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0337 mg/mLALOGPS
logP3.69ALOGPS
logP2.65ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)4.36ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area107.22 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity112.75 m3·mol-1ChemAxon
Polarizability44.49 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Long-chain fatty acids / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Hydroxy fatty acids / Halogenated fatty acids / Chlorobenzenes / Unsaturated fatty acids / Aryl chlorides / Cyclopentanols
show 7 more
Substituents
Prostaglandin skeleton / Long-chain fatty acid / Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Halogenated fatty acid / Hydroxy fatty acid / Fatty acid
show 21 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on February 26, 2016 10:27 / Updated on March 01, 2020 23:38

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates